Bis-4,9-diazapyrenium dications: Synthesis of the methylenedibenzyl- analogue, interactions with nucleotides, DNA, RNA. The antitumour activity of all till now prepared analogues

Journal of Physical Organic Chemistry

Volumn 20, Issue 4, 2007, Pages 285-295

  Piantanida, Ivo ^a   Žinić, Mladen ^a   Marczi, Saška ^b   Glavaš Obrovac, Ljubica ^b,c  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^c School of Medicine Osijek   (Croatia)

Author keywords

Antiproliferative activity; Antitumour activity; Bis 4,9 diazapyrenium cations; DNA; Intercalation; RNA

Indexed keywords

DNA; MOLECULAR STRUCTURE; NUCLEOTIDES; RNA; SYNTHESIS (CHEMICAL); TUMORS;

ANTIPROLIFERATIVE ACTIVITY; ANTITUMOUR ACTIVITY; AROMATIC STACKING INTERACTIONS; BIS-4,9-DIAZAPYRENIUM CATIONS;

AROMATIC COMPOUNDS;

EID: 34248563071     PISSN: 08943230     EISSN: 10991395     Source Type: Journal    
DOI: 10.1002/poc.1165     Document Type: Article

References (42)

1. (a) Hertzberg RP. In Comprehensive Medicinal Chemistry, vol. 2, Hansch C, Sammes PG, Taylor JB (eds). Pergamon: Oxford, 1990; pp 753-791;
2. (b) Ralph RK, Judd W, Kohn KW. In Molecular Aspects of Anticancer Drug - DNA Interactions, vol. 2, Neidle S, Waring M (eds). CRC: Boca Raton FL, 1994;
3. (c) Wilson WD. In Nucleic Acids in Chemistry and Biology. 2nd edition, Blackburn M, Gait M (eds). IRL Press: Oxford, 1996.
4. (a) Demeunynck M, Bailly C, Wilson WD. In DNA and RNA Binders. Wiley-VCH: Weinheim, 2002;
5. (b) Saenger W. In Principles of Nucleic Acid Structure. Springer: New York, 1988.
6. (a) Luedtke NW, Liu Q, Tor Y. Bioorg. Med. Chem. 2003; 11: 5235-5247;
7. (b) Luedtke NW, Hwang JS, Nava E, Gut D, Kol M, Tor Y. Nucleic Acids Res. 2003; 31: 5732-5740.
8. Kubar T, Hanus M, Ryjacek F, Hobza P. Chem. Eur. J. 2005; 12: 280-290.
9. (a) Luedtke NW, Liu Q, Tor Y. Chem. Eur. J. 2005; 11: 495-508;
10. (b) Tam VK, Liu Q, Tor Y. Chem. Commun. 2006; 2684-2686.
11. (a) Blacker J, Jazwinski J, Lehn J-M. Helv. Chim. Acta 1987; 70: 1-11;
12. (b) Blacker J, Jazwinski J, Lehn J-M, Wilhelm FX. J. Chem. Soc., Chem. Commun. 1986; 1035;
13. (c) Slama-Schwok A, Jazwinski J, Bere A, Montenay-Garestier T, Rougge M, Hélène C, Lehn J-M. Biochemistry 1989; 8: 3227-3234;
14. (d) Slama-Schwok A, Rougge M, Ibanez V, Geacintov NE, Montenay-Garestier T, Lehn J-M, Hélène C. Biochemistry 1989; 8: 3234-3242;
15. (e) Brun AM, Harriman A. J. Am. Chem. Soc. 1991; 113: 8153-8159;
16. (f) Coudret C, Harriman A. J. Chem. Soc. Chem. Commun. 1992; 1755-1757.
17. Piantanida I, Tomišić V, Žinić M. J. Chem, Soc., Perkin Trans. 2 2000; 375-383.
18. (a) Yu D-H, MacDonald J, Josephs S, Liu Q, Nguy V, Tor Y, Wong-Staal F, Li Q-X. Invest. New Drugs 2006; 24: 489-498;
19. (b) Steiner-Biočić I, Glavaš-Obrovac Lj, Karner I, Piantanida I, Žinić M, Pavelić K, Pavelić J. Anticancer Res. 1996; 16: 3705-3708;
20. (c) Roknić S, Glavaš-Obrovac Lj, Karner I, Piantanida I, Žinić M, Pavelić K. Chemotherapy 2000; 46: 143-148;
21. (d) Marczi S, Glavaš-Obrovac Lj, Karner I. Chemotherapy 2005; 51: 217-222.
22. Palm BS, Piantanida I, Žinić M, Schneider H-J. J. Chem. Soc., Perkin Trans. 2 2000; 385-392.
23. Piantanida I, Palm BS, Žinić M, Schneider H-J. J. Chem. Soc., Perkin Trans. 2 2001; 1808-1816.
24. (a) Kuruvilla E, Joseph J, Ramaiah D. J. Phys. Chem. B 2005; 109: 21997-22002;
25. (b) Joseph J, Eldho NV, Ramaiah D. Chem. Eur. J. 2003; 9: 5926-5935;
26. (c) Carrasco C, Helissey P, Haroun M, Baldeyrou B, Lansiaux A, Colson P, Houssier C, Giorgi-Renault S, Bailly C. Chem. Bio. Chem. 2003; 4: 50-61;
27. (d) Bolognesi ML, Andrisano V, Bartolini M, Banzi R, Melchiorre C. J. Med. Chem. 2005; 48: 24-27.
28. Mosby WL. J. Org. Chem. 1957; 22: 671-673.
29. Specfit Global Analysis, a program for fitting, equilibrium and kinetic systems, using factor analysis & Marquardt minimization; (a) Gampp H, Maeder M, Meyer CJ, Zuberbuehler AD. Talanta 1985; 32:257-264;
30. (b) Maeder M, Zuberbuehler AD. Anal. Chem. 1990; 62: 2220-2224.
31. Dougherty G, Pilbrow JR. Int. J. Biochem. 1984; 16: 1179-1192.
32. Pal MK, Ghosh JK. Spectrochim. Acta Part A 1995; 51: 489-498.
33. Scatchard G. Ann. N. Y. Acad. Sci. 1949; 51: 660-672.
34. McGhee JD, von Hippel PH. J. Mol. Biol. 1976; 103: 679-684.
35. Wakelin JPG. Med. Res. Rev. 1986; 6: 275-340.
36. Cantor CR, Schimmel PR. In Biophysical Chemistry, vol. 3. Freeman WH, and Co.: San Francisco, 1980;
37. Wilson WD, Tanious FA, Fernandez-Saiz M, Rigl CT. In Evaluation of Drug/Nucleic Acid Interactions by Thermal Melting Curves: Methods in Molecular Biology, vol. 90, Drug-DNA Interaction Protocols, Fox KR (ed.). Humana Press Inc.: Totowa, NY, 1998.
38. Boger DL, Fink BE, Brunette SR, Tse WC, Hedrick MP. J. Am. Chem. Soc. 2001; 123: 5878-5891.
39. Rodger A, Norden B. In Circular Dichroism and Linear Dichroism. Oxford University Press: New York, 1997;
40. Raghunand N, Gillies RJ. Drug Resist. Updat. 2000; 3: 39-47.
41. Chaires JB, Dattagupta N, Crothers DM. Biochemistry 1982; 21: 3933-3940.
42. Horiuchi N, Nakagawa K, Sasaki Y, Minato K, Fujiwara Y, Nezu K, Ohe Y, Saijo N. Cancer Chemother. Pharmacol. 1988; 22: 246-250.